ANIPANI Pharmaceuticals, Inc.

$2B

Q3 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$48M+25.0% YoY

Gross Profit

$27M56.2% margin

Operating Income

$9M19.4% margin

Net Income

$5M9.7% margin

EPS (Diluted)

$0.40

QoQ Revenue Growth

+7.6%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$15M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$370M

Total Liabilities

$188M

Stockholders' Equity

$183M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$39M	+25.0%
Gross Profit	$27M	$22M	+23.9%
Operating Income	$9M	$8M	+17.8%
Net Income	$5M	$3M	+85.5%

Revenue Segments

Unapproved Products

$8M100%

ANIP Q3 2017 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena